MacroGenics Inc ((MGNX)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
MacroGenics Inc. is conducting a Phase 1 clinical trial titled A Phase 1, First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC028 in Participants With Advanced Solid Tumors. The study aims to evaluate the safety, tolerability, and optimal dosing of MGC028, an antibody-drug conjugate targeting ADAM9, in patients with advanced solid tumors. The primary objective is to identify potential side effects and assess the drug’s ability to control tumor progression.
MGC028, the intervention being tested, is a biological treatment designed to target and combat advanced solid tumors by leveraging its action against the ADAM9 protein.
The study follows a non-randomized, sequential intervention model with no masking, focusing primarily on treatment. Participants are divided into multiple cohorts to receive varying doses of MGC028, with the goal of determining the maximum tolerated dose.
The study began on December 4, 2024, with the latest update submitted on September 16, 2025. These dates are crucial as they mark the progression and current status of the trial, which is still recruiting participants.
This study update could influence MacroGenics’ stock performance by potentially boosting investor confidence if the results show promise in treating advanced solid tumors. It also positions MacroGenics competitively within the oncology sector, where advancements in targeted therapies are highly sought after.
The study is ongoing, with further details available on the ClinicalTrials portal.